NEW YORK (
CHANGE IN RATINGS
downgraded at Citigroup to Neutral from Buy, Citigroup said. $29 price target. More balanced risk/reward outlook.
(BRCM - Get Report)
rated new Buy at Cantor. $40 price target. Infrastructure business trends remain strong and the NetLogic purchase should boost growth.
rated new Sell at Goldman. $39 price target. Company faces multiple growth headwinds.
(F - Get Report)
rated new Hold at Stifel. Company had been losing market share but is now better positioned for the next major product cycle.
upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $9 price target. Stock appears oversold and sports a 4% dividend yield.
rated new Market Perform at Wells. IT was initiated with a Market Perform rating, Wells Fargo said. Company is leveraged to near-term IT spending concerns.
downgraded at Baird from Outperform to Neutral, Robert Baird said. Valuation call, based on a $37 price target.
upgraded at Benchmark from Hold to Buy, Benchmark said. $53 price target. Company has strong growth prospects in finance and can unlock value by separating the education business.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Valuation call, following the recent pullback.
(QCOM - Get Report)
rated new Buy at Cantor Fitzgerald. $66 price target. Long-term trends remain positive for wireless devices.
rated new Strong Buy at Needham. $25 price target. Stock looks oversold at current levels.
upgraded at UBS to Buy from Neutral, UBS said. $31 price target. Prices already reflect NGL weakness.
rated new Equal-weight at Piper. Overall market outlook remains uncertain.
Western Gas Partners
upgraded at UBS to Buy from Neutral, UBS said. $48 price target. Continue to expect strong distribution growth.
downgraded at Goldman to Sell, Goldman Sachs said. $24 price target. Company is leveraged to softer European and municipal water markets.
STOCK COMMENTS / EPS CHANGES
(ARNA - Get Report)
numbers increased at BMO. ARNA estimates were raised through 2013, BMO Capital said. Company received better labeling in its FDA approval. Market Perform rating and new $12 price target.
Arena Pharmaceuticals target raised at Jefferies. Shares of ARNA now seen reaching $20, Jefferies said. FDA approves Lorcaserin. Buy rating.